Factors predicting treatment responsiveness and prognosis in node-negative breast cancer

A. M. Neville, R. Bettelheim, R. D. Gelber, J. Säve-Söderberght, B. W. Davis, R. Reed, J. Torhorst, R. Golouh, H. F. Peterson, K. N. Price, M. Isley, C. M. Rudenstam, J. Collins, M. Castiglione, H. J. Senn, A. Goldhirsch

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Purpose: An international trial (formerly Ludwig Trial V) has been conducted in 1,275 subjects to ascertain if perioperative chemotherapy is beneficial for nodenegative breast cancer patients and to identify subgroups of patients who benefit from this therapy. Patients and Methods: Node-negative breast cancer patients were randomized to receive either one cycle of perioperative chemotherapy or no adjuvant treatment. A detailed pathology review was conducted in 1,203 of the 1,275 patients enrolled. Stepwise Cox regression analysis was used to search for factors either predicting chemotherapeutic responsiveness and/or influencing disease-free survival (DFS). Results: As expected, primary tumor size, grade, and the presence of peritumoral vascular invasion are the most important prognostic factors. Perioperative chemotherapy provides a DFS advantage at 5 years of median follow-up and such treatment is more effective for estrogen receptor-negative than for estrogen receptor-positive tumors, for histologic grade 2 and 3 than for grade 1 tumors, and for patients in whom no axillary lymph node metastases were found even after serial sectioning and review by the Central Pathology Laboratory. Conclusion: Hormone receptor status and tumor grade are important factors for predicting responsiveness to perioperative chemotherapy in node-negative breast cancer.

Original languageEnglish
Pages (from-to)696-705
Number of pages10
JournalJournal of Clinical Oncology
Volume10
Issue number5
Publication statusPublished - 1992

Fingerprint

Breast Neoplasms
Drug Therapy
Estrogen Receptors
Disease-Free Survival
Neoplasms
Therapeutics
Pathology
Blood Vessels
Lymph Nodes
Regression Analysis
Hormones
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neville, A. M., Bettelheim, R., Gelber, R. D., Säve-Söderberght, J., Davis, B. W., Reed, R., ... Goldhirsch, A. (1992). Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. Journal of Clinical Oncology, 10(5), 696-705.

Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. / Neville, A. M.; Bettelheim, R.; Gelber, R. D.; Säve-Söderberght, J.; Davis, B. W.; Reed, R.; Torhorst, J.; Golouh, R.; Peterson, H. F.; Price, K. N.; Isley, M.; Rudenstam, C. M.; Collins, J.; Castiglione, M.; Senn, H. J.; Goldhirsch, A.

In: Journal of Clinical Oncology, Vol. 10, No. 5, 1992, p. 696-705.

Research output: Contribution to journalArticle

Neville, AM, Bettelheim, R, Gelber, RD, Säve-Söderberght, J, Davis, BW, Reed, R, Torhorst, J, Golouh, R, Peterson, HF, Price, KN, Isley, M, Rudenstam, CM, Collins, J, Castiglione, M, Senn, HJ & Goldhirsch, A 1992, 'Factors predicting treatment responsiveness and prognosis in node-negative breast cancer', Journal of Clinical Oncology, vol. 10, no. 5, pp. 696-705.
Neville AM, Bettelheim R, Gelber RD, Säve-Söderberght J, Davis BW, Reed R et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. Journal of Clinical Oncology. 1992;10(5):696-705.
Neville, A. M. ; Bettelheim, R. ; Gelber, R. D. ; Säve-Söderberght, J. ; Davis, B. W. ; Reed, R. ; Torhorst, J. ; Golouh, R. ; Peterson, H. F. ; Price, K. N. ; Isley, M. ; Rudenstam, C. M. ; Collins, J. ; Castiglione, M. ; Senn, H. J. ; Goldhirsch, A. / Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 5. pp. 696-705.
@article{34755a111c3a4295a170d7c8a17355fe,
title = "Factors predicting treatment responsiveness and prognosis in node-negative breast cancer",
abstract = "Purpose: An international trial (formerly Ludwig Trial V) has been conducted in 1,275 subjects to ascertain if perioperative chemotherapy is beneficial for nodenegative breast cancer patients and to identify subgroups of patients who benefit from this therapy. Patients and Methods: Node-negative breast cancer patients were randomized to receive either one cycle of perioperative chemotherapy or no adjuvant treatment. A detailed pathology review was conducted in 1,203 of the 1,275 patients enrolled. Stepwise Cox regression analysis was used to search for factors either predicting chemotherapeutic responsiveness and/or influencing disease-free survival (DFS). Results: As expected, primary tumor size, grade, and the presence of peritumoral vascular invasion are the most important prognostic factors. Perioperative chemotherapy provides a DFS advantage at 5 years of median follow-up and such treatment is more effective for estrogen receptor-negative than for estrogen receptor-positive tumors, for histologic grade 2 and 3 than for grade 1 tumors, and for patients in whom no axillary lymph node metastases were found even after serial sectioning and review by the Central Pathology Laboratory. Conclusion: Hormone receptor status and tumor grade are important factors for predicting responsiveness to perioperative chemotherapy in node-negative breast cancer.",
author = "Neville, {A. M.} and R. Bettelheim and Gelber, {R. D.} and J. S{\"a}ve-S{\"o}derberght and Davis, {B. W.} and R. Reed and J. Torhorst and R. Golouh and Peterson, {H. F.} and Price, {K. N.} and M. Isley and Rudenstam, {C. M.} and J. Collins and M. Castiglione and Senn, {H. J.} and A. Goldhirsch",
year = "1992",
language = "English",
volume = "10",
pages = "696--705",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Factors predicting treatment responsiveness and prognosis in node-negative breast cancer

AU - Neville, A. M.

AU - Bettelheim, R.

AU - Gelber, R. D.

AU - Säve-Söderberght, J.

AU - Davis, B. W.

AU - Reed, R.

AU - Torhorst, J.

AU - Golouh, R.

AU - Peterson, H. F.

AU - Price, K. N.

AU - Isley, M.

AU - Rudenstam, C. M.

AU - Collins, J.

AU - Castiglione, M.

AU - Senn, H. J.

AU - Goldhirsch, A.

PY - 1992

Y1 - 1992

N2 - Purpose: An international trial (formerly Ludwig Trial V) has been conducted in 1,275 subjects to ascertain if perioperative chemotherapy is beneficial for nodenegative breast cancer patients and to identify subgroups of patients who benefit from this therapy. Patients and Methods: Node-negative breast cancer patients were randomized to receive either one cycle of perioperative chemotherapy or no adjuvant treatment. A detailed pathology review was conducted in 1,203 of the 1,275 patients enrolled. Stepwise Cox regression analysis was used to search for factors either predicting chemotherapeutic responsiveness and/or influencing disease-free survival (DFS). Results: As expected, primary tumor size, grade, and the presence of peritumoral vascular invasion are the most important prognostic factors. Perioperative chemotherapy provides a DFS advantage at 5 years of median follow-up and such treatment is more effective for estrogen receptor-negative than for estrogen receptor-positive tumors, for histologic grade 2 and 3 than for grade 1 tumors, and for patients in whom no axillary lymph node metastases were found even after serial sectioning and review by the Central Pathology Laboratory. Conclusion: Hormone receptor status and tumor grade are important factors for predicting responsiveness to perioperative chemotherapy in node-negative breast cancer.

AB - Purpose: An international trial (formerly Ludwig Trial V) has been conducted in 1,275 subjects to ascertain if perioperative chemotherapy is beneficial for nodenegative breast cancer patients and to identify subgroups of patients who benefit from this therapy. Patients and Methods: Node-negative breast cancer patients were randomized to receive either one cycle of perioperative chemotherapy or no adjuvant treatment. A detailed pathology review was conducted in 1,203 of the 1,275 patients enrolled. Stepwise Cox regression analysis was used to search for factors either predicting chemotherapeutic responsiveness and/or influencing disease-free survival (DFS). Results: As expected, primary tumor size, grade, and the presence of peritumoral vascular invasion are the most important prognostic factors. Perioperative chemotherapy provides a DFS advantage at 5 years of median follow-up and such treatment is more effective for estrogen receptor-negative than for estrogen receptor-positive tumors, for histologic grade 2 and 3 than for grade 1 tumors, and for patients in whom no axillary lymph node metastases were found even after serial sectioning and review by the Central Pathology Laboratory. Conclusion: Hormone receptor status and tumor grade are important factors for predicting responsiveness to perioperative chemotherapy in node-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026663624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026663624&partnerID=8YFLogxK

M3 - Article

C2 - 1569442

AN - SCOPUS:0026663624

VL - 10

SP - 696

EP - 705

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -